<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95387</article-id><article-id pub-id-type="doi">10.26442/20751753.2021.1.200572</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Hyperuricemia as a risk factor of contrast-induced acute kidney injury</article-title><trans-title-group xml:lang="ru"><trans-title>Гиперурикемия как фактор риска контраст-индуцированного острого повреждения почек</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mironova</surname><given-names>Olga lu.</given-names></name><name xml:lang="ru"><surname>Миронова</surname><given-names>Ольга Юрьевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. факультетской терапии</p></bio><email>mironova_o_yu@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lakotka</surname><given-names>Polina G.</given-names></name><name xml:lang="ru"><surname>Лакотка</surname><given-names>Полина Геннадьевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант каф. факультетской терапии</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fomin</surname><given-names>Viktor V.</given-names></name><name xml:lang="ru"><surname>Фомин</surname><given-names>Виктор Викторович</given-names></name></name-alternatives><bio xml:lang="ru"><p>чл.-кор. РАН, д-р мед. наук, проф., проректор по клинической работе и дополнительному профессиональному образованию, зав. каф. факультетской терапии</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2021</year></pub-date><volume>23</volume><issue>1</issue><issue-title xml:lang="en">VOL 23, NO1 (2021)</issue-title><issue-title xml:lang="ru">ТОМ 23, №1 (2021)</issue-title><fpage>25</fpage><lpage>27</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/95387">https://consilium.orscience.ru/2075-1753/article/view/95387</self-uri><abstract xml:lang="en"><p>Aim. To assess the prevalence of contrast-induced acute kidney injury (CI-AKI) in patients with stable coronary artery disease (CAD) and hyperuricemia. Materials and methods. Patients with stable CAD receiving optimal medical therapy and with indications to coronary angiography and possible coronary angioplasty were included in an observational open prospective cohort study. The protocol of the study was registered in clinicaltrials.gov with ID NCT04014153. We conducted a sub-analysis of the group of patients with hyperuricemia (uric acid level &gt;7 mg/dl). Results. We included 1023 patients with stable CAD. 32 patients suffered from hyperuricemia. The rate of CI-AKI in this group was 6.25% (2 patients), that was lower than in patients with normal levels of uric acid (13.1%). The difference was not statistically significant probably due to the small number of patients with hyperuricemia. The patients with hyperuricemia had proteinuria 3 times more frequently, than patients without, the rate of diabetes mellitus was 7% higher as well as anemia by 4.5% but didn’t reach statistical significance. Conclusion. The rate of CI-AKI in patients with hyperuricemia was twice lower than in patients with normal levels of uric acid. More research needs to be conducted in patients with metabolic syndrome in larger groups.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Оценить частоту контраст-индуцированного острого повреждения почек (КИ-ОПП) у пациентов со стабильной ишемической болезнью сердца (ИБС) и гиперурикемией. Материалы и методы. В наблюдательное открытое проспективное когортное исследование включены пациенты со стабильной ИБС, получающие оптимальную медикаментозную терапию и имеющие показания к проведению исследований с внутриартериальным введением контрастных веществ. Протокол зарегистрирован в системе clinicaltrials.gov под номером NCT04014153. Нами проведен субанализ группы пациентов с гиперурикемией (уровнем мочевой кислоты выше 7 мг/дл). Результаты. Мы включили 1023 пациентов со стабильной ИБС. Страдали гиперурикемией 32 пациента. Частота КИ-ОПП в этой группе составила 6,25% (2 пациента), что оказалось в 2 раза ниже, чем у пациентов с нормальным уровнем мочевой кислоты (13,1%). Различия статистически незначимы. У пациентов с гиперурикемией в 3 раза чаще отмечались протеинурия, на 7% чаще - сахарный диабет и на 4,5% - анемия, однако полученные данные также статистически незначимы, по-видимому, с учетом малого размера выборки. Заключение. Частота КИ-ОПП у пациентов с гиперурикемией в 2 раза ниже, чем у пациентов с нормальным уровнем мочевой кислоты. Необходимо проведение большего количества исследований у пациентов с метаболическим синдромом с большими выборками.</p></trans-abstract><kwd-group xml:lang="en"><kwd>contrast-induced acute kidney injury</kwd><kwd>contrast-associated acute kidney injury</kwd><kwd>contrast-induced nephropathy</kwd><kwd>coronary artery disease</kwd><kwd>percutaneous coronary intervention</kwd><kwd>contrast</kwd><kwd>hyperuricemia</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>контраст-индуцированное острое повреждение почек</kwd><kwd>контраст-ассоциированное острое повреждение почек</kwd><kwd>контраст-индуци-рованная нефропатия</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>чрескожное коронарное вмешательство</kwd><kwd>контрастное вещество</kwd><kwd>гиперурикемия</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Cheungpasitporn W, Thongprayoon C, Harrison AM, Erickson SB. Admission hyperuricemia increases the risk of acute kidney injury in hospitalized patients. Clin Kidney J 2016; 9 (1): 51-6.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kang MW, Chin HJ, Joo KW, et al. Hyperuricemia is associated with acute kidney injury and allcause mortality in hospitalized patients. Nephrology 2019; 24 (7): 718-24.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Xu X, Hu J, Song N, et al. Hyperuricemia increases the risk of acute kidney injury: A systematic review and meta-analysis. BMC Nephrol 2017; 18 (1): 1-14. DOI: 10.1186/s12882-016-0433-1</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76 (1): 29-42.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003; 361 (9351): 13-20.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Guo W, Song F, Chen S, et al. The relationship between hyperuricemia and contrast-induced acute kidney injury undergoing primary percutaneous coronary intervention: Secondary analysis protocol for the ATTEMPT RESCIND-1 study. Trials 2020; 21 (1): 1-5.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>KDIGO Working Group. Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;(1): 124-38. Available at: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO AKI Gui-deline.pdf</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Williams B, Mancia G, De Backer G, et al. 2018 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2018; 25 (6): 1105-87.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37 (27): 2129-200m.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Diabetes Mellit 2017; 20 (1S): 1-112.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Khanna D, Fitzegarld J, Khanna P, et al. 2012 American College of Rheumatology Guidelines for Management of Gout Part I: Systematic Non-pharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care Res 2012; 64 (10): 1431-46. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3683400%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.f cgi?artid=PMC368044</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Алиментарные анемии. Доклад научной группы ВОЗ. Женева, 1970</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004; 44 (7): 1393-9. DOI: 10.1016/j.jacc.2004.06.068</mixed-citation></ref></ref-list></back></article>
